Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials.

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Abstract Text:

The insulin-like growth factor-I receptor (IGF-IR) was first cloned in 1986. Since then, intense work has defined classic phosphorelays activated via the IGF-IR, which regulate cell proliferation, apoptosis, motility, and fate. The understanding of the roles of hormones in cancer and the growth hormone-IGF-IGF-binding protein axis specifically has yield to a second wave of development: the design of specific inhibitors that interrupt the signaling associated with this axis. The ability to manipulate these pathways holds not only significant therapeutic implications but also increase the chance of deeper insight about the role of the axis in carcinogenesis and metastasis. Nowadays, >25 molecules with the same goal are at different stages of development. Here, we review the clinical and preclinical experience with the two most-investigated strategies, tyrosine kinase inhibitors and monoclonal antibodies, and the advantages and disadvantages of each strategy, as well as other alternatives and possible drug combinations. We also review the biomarkers explored in the first clinical trials, the strategies that have been explored thus far, and the clinical trials that are going to explore their role in cancer treatment. [Mol Cancer Ther 2008;7(9):2575-88].

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Molecular cancer therapeutics

VOLUME: 7

Page Numbers: 2575-88

Journal Abbreviation: Mol. Cancer Ther.

ISSN: 1535-7163

DAY: 15

MONTH: Sep

YEAR: 2008

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101132535

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials.

AFFILIATION: Investigational Cancer Therapeutics, University of Texas M. D. Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030. jrodonahnert@gmail.com.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Mol Cancer Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials Related Publications

• Beta1 integrin expression pattern in transitional urothelium does not allow for efficient stem cell enrichment as in other epithelia.
• Complete bladder duplication presenting as incontinence in an 11-year-old girl.
• Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.
• Cutaneous castleman's disease responds to anti interleukin-6 treatment.
• Development and validation of the fecal incontinence and constipation quality of life measure in children with spina bifida.
• Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials.
• How do we measure hypospadias outcomes?
• Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.
• Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics.
• Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
• Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
• Non-surgical management of multicystic dysplastic kidney.
• Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
• Short stay pyeloplasty: variables affecting pain and length of stay.
• Studies in target-based treatment.
• The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
• [Vinca rosea in the treatment of hemoblastoses and similar clinical pictures.]